Wednesday, November 22, 2006 10:07:36 AM
Lumpy, thanks for the quick reply. I have the same impression.
To add:
There is no adequat treatment for GVHD except from Prednisone.
Orbec has no side effects. The drug missed the primary endpoint
short term but fullfilled 80 and 200 days overall survival rate. Please comment. For the FDA there is not a big risk to
approve the drug. Your comparison with dndn is good. I think
Dor is in a better situation because Dndn drug is taylormade
for each patient. Orbec is a drug that fits for every patient.
Is this a opportunity that is flying under the radar? Why is it
sticking around at 27 cents? The price is absolutely ridiculous.
To add:
There is no adequat treatment for GVHD except from Prednisone.
Orbec has no side effects. The drug missed the primary endpoint
short term but fullfilled 80 and 200 days overall survival rate. Please comment. For the FDA there is not a big risk to
approve the drug. Your comparison with dndn is good. I think
Dor is in a better situation because Dndn drug is taylormade
for each patient. Orbec is a drug that fits for every patient.
Is this a opportunity that is flying under the radar? Why is it
sticking around at 27 cents? The price is absolutely ridiculous.
Recent SNGX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 • PR Newswire (US) • 03/23/2026 11:30:00 AM
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency • PR Newswire (US) • 03/10/2026 11:30:00 AM
- Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 02/26/2026 12:30:00 PM
- Soligenix to Present at BIO Investment & Growth Summit • PR Newswire (US) • 02/24/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:05:19 PM
- Soligenix Details Recent Progress and Upcoming Milestones • PR Newswire (US) • 02/12/2026 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/23/2026 09:31:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 09:05:35 PM
- Soligenix Shares Jump on Encouraging Data for Behçet’s Disease Therapy • IH Market News • 12/18/2025 03:30:21 PM
- Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) • PR Newswire (US) • 12/18/2025 12:30:00 PM
